• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

    12/20/23 6:27:44 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SHORT JAY M PHD

    (Last) (First) (Middle)
    C/O BIOATLA, INC. 11085 TORREYANA ROAD

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BioAtla, Inc. [ BCAB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    12/20/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/20/2023 P 50,000 A $2.1382(1) 1,439,283 D
    Common Stock 793,547 I By Spouse
    Common Stock 258,727 I By Carolyn Short 2020 Irrevocable Gift Trust
    Common Stock 258,727 I By Jay Short 2020 Irrevocable Gift Trust
    Common Stock 302,324 I By Capia IP, LLC
    Common Stock 50 I By Himalaya Parent LLC(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The range of prices for the shares of Common Stock is from $2.02 to $2.215. The Reporting Person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price.
    2. The Reporting Person and his spouse are the managers of Himalaya Parent LLC and collectively make investment decisions on the behalf of the entity. The Reporting Person and his spouse disclaim beneficial ownership of the reported securities except to the extent of his or her pecuniary interest therein.
    Remarks:
    /s/ Christian Vasquez, as Attorney-in-Fact for Jay M. Short 12/20/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    8/13/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    SEC Filings

    View All

    SEC Form DEF 14A filed by BioAtla Inc.

    DEF 14A - BioAtla, Inc. (0001826892) (Filer)

    12/5/25 4:05:09 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by BioAtla Inc.

    PRE 14A - BioAtla, Inc. (0001826892) (Filer)

    11/24/25 8:00:14 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by BioAtla Inc.

    424B5 - BioAtla, Inc. (0001826892) (Filer)

    11/21/25 8:33:34 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

    These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to complete the transaction by year endThese agreements ensure BioAtla can maintain operational momentum while completing that process SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into Pre-paid Advance Agreements with a

    11/21/25 12:25:45 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

    Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half of 2026Achieved milestone with Context Therapeutics under the license agreement for the CAB-Nectin4-TCE reflecting continued progress and validation of BioAtla's differentiated CAB T-cell

    11/13/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

    — Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced clinical data in a poster t

    11/7/25 9:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Waldron Richard A covered exercise/tax liability with 2,371 shares, decreasing direct ownership by 0.68% to 346,150 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/1/25 6:37:25 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Sievers Eric covered exercise/tax liability with 2,729 shares, decreasing direct ownership by 0.75% to 361,845 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/1/25 6:35:22 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 6,347 shares, decreasing direct ownership by 0.28% to 2,237,331 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/1/25 6:35:06 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioAtla downgraded by Citizens JMP

    Citizens JMP downgraded BioAtla from Mkt Outperform to Mkt Perform

    8/13/25 8:01:09 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla downgraded by H.C. Wainwright

    H.C. Wainwright downgraded BioAtla from Buy to Neutral

    11/13/24 7:31:56 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    JMP Securities initiated coverage on BioAtla with a new price target

    JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

    9/15/22 7:31:28 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    1/19/24 4:21:50 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/26/23 7:43:02 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

    4 - BioAtla, Inc. (0001826892) (Issuer)

    12/20/23 6:27:44 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Financials

    Live finance-specific insights

    View All

    BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

    Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year endBA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half of 2026Achieved milestone with Context Therapeutics under the license agreement for the CAB-Nectin4-TCE reflecting continued progress and validation of BioAtla's differentiated CAB T-cell

    11/13/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

    SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2025 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, November 13, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2025 Earnings Conference CallDial-in Numbers: (800)-343-4136 (domestic), (203) 518-9843 (internation

    11/5/25 8:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

    CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study ongoing; meeting planned with U.S. Food & Drug Administration (FDA) in 3Q 2025 to discuss proposed Phase 3 study design Company is advancing partnering discussions and remains confident in our goal to close at least one transaction in 2025 Management to host conference call and webcast today at 4:30 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology co

    8/7/25 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    View All

    BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

    SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

    12/21/21 9:00:00 AM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

    SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

    11/14/24 4:00:05 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    10/2/24 4:30:04 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

    SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

    9/6/24 4:59:38 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care